BioSpace News Archive

Inhibikase Therapeutics, Inc. today announced dosing of the first Parkinson’s patient in its Phase 1b clinical trial of IkT-148009, an Abelson Tyrosine Kinase, or c-Abl, inhibitor for the treatment of Parkinson’s disease.

Axcella Therapeutics today announced that it will host a virtual R&D Day on Tuesday, October 26, 2021, at 10:00 a.m. ET.

Curebase, a company committed to democratizing access to clinical studies, and Checkable Medical, a startup that offers unique at-home tests for strep throat, today announced a joint clinical trial designed to confirm the efficacy and accuracy of Checkable’s at-home strep throat test kits.

Edesa Biotech, Inc. today announced additional results from the Phase 2 part of an ongoing Phase 2/3 clinical study evaluating the company’s monoclonal antibody candidate, designated EB05, as a single-dose treatment for hospitalized COVID-19 patients.

Verogen Inc., a dedicated developer of human identification products for sequencing and analysis of forensic genomic samples, is building on its partnership with Cellmark Forensic Services.

Targovax ASA today announces that members of its executive management team are invited to present and participate in upcoming conferences. Økonomisk Ugebrev’s Life Science Investor conference Date: 20 October 2021 Presenter: Lone Ottesen (CDO) Time: 14:35 CET

Engagement will combine MASORI’ s global platforms and commercial experience in Japan to identify partnerships t hat leverage Vyant Bio’s advanced analytics and complex human-derived biology to drive drug discovery

Credence MedSystems, Inc. announced today that it has formed a strategic collaboration with Phillips-Medisize, a Molex company, a global leader in the design and manufacturing of solutions for the pharmaceutical drug delivery market.

COUR Pharmaceuticals, a biotechnology company developing novel immune-modifying nanoparticles to treat immune disorders (CNPs), today announced that the first patient has been dosed in the Company’s first-in-human proof-of-concept (Phase 1b/2a) of its lead candidate, CNP-201, for the treatment of peanut allergy.

Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company announced today having been awarded the third phase funding to advance the development of its antibiotic program, Debio 1453, by the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a Boston-based non-profit accelerating antibacterial research.